Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...
Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.53 per share a year ago. These ...
One of the biggest complaints about modern horror movies is that it's much more cost-effective and much faster to rely on digital effects as opposed to practical effects. No matter how sophisticated ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果